Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mergæxli - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mergæxli - Æxlishemjandi lyf - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - brjóstakrabbamein - Æxlishemjandi lyf - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - Ónæmisbælandi lyf - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mergæxli - Æxlishemjandi lyf - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - amoxicillinum tríhýdrat - tafla - 750 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - amoxicillinum tríhýdrat - hart hylki - 500 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

n.v. organon* - betamethasonum díprópíónat; acidum salicylicum - húðlausn

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - clarithromycinum inn - filmuhúðuð tafla - 500 mg